Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
This approval showcases Teva’s proven strengths in complex generic formulations development and device engineering
Phase 3 data expected in the second half of 2024
Lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma.
George Svokos joins Avet after serving as a strategic business advisor to numerous global healthcare companies
Subscribe To Our Newsletter & Stay Updated
